Shanghai, China
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) stands as a leading global player in the pharmaceutical sector, focused on pioneering research, development, and commercialization of innovative medications. Since its inception in 1970, the company has steadfastly adhered to its mission of addressing unmet clinical needs across critical therapeutic areas including oncology, metabolic and cardiovascular maladies, immunological and respiratory conditions, and neuroscience.
With an expansive R&D framework comprising 14 R&D centers and over 5,500 professionals, Hengrui Pharma has successfully launched 19 new molecular entity drugs and 4 other innovative drugs primarily in China. This commitment to innovation is further evidenced by a substantial $500.00M post-IPO equity investment received on 01 July 2025, underscoring remarkable investor confidence in their robust pipeline.
As Hengrui Pharma continues to leverage the power of science and technology, it remains focused on its core principle of 'putting patients first', aiming to advance human health by conquering diseases, enhancing health, and extending lives.
Laminar Pharma